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Abstract
Cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1
(PD‐1) are immune checkpoint proteins expressed in T cells. Although CTLA4
expression was found in multiple tumours including non‐small cell lung cancer
(NSCLC) tissues and cells, its function in tumour cells is unknown. Recently, PD‐1
was found to be expressed in melanoma cells and to promote tumorigenesis. We
found that CTLA4 was expressed in a subset of NSCLC cell lines and in a subgroup
of cancer cells within the lung cancer tissues. We further found that in NSCLC cells,
anti‐CTLA4 antibody can induce PD‐L1 expression, which is mediated by CTLA4
and the EGFR pathway involving phosphorylation of MEK and ERK. In CTLA4
knockout cells, EGFR knockout cells or in the presence of an EGFR tyrosine kinase
inhibitor, anti‐CTLA4 antibody was not able to induce PD‐L1 expression in NSCLC
cells. Moreover, anti‐CTLA4 antibody promoted NSCLC cell proliferation in vitro
and tumour growth in vivo in the absence of adaptive immunity. These results sug-
gest that tumour cell‐intrinsic CTLA4 can regulate PD‐L1 expression and cell prolif-
eration, and that anti‐CTLA4 antibody, by binding to the tumour cell‐intrinsic
CTLA4, may result in the activation of the EGFR pathway in cancer cells.
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1 | INTRODUCTION
Anti‐cytotoxic T lymphocyte antigen 4 (CTLA4) antibodies have
been shown to reverse T cell anergy leading to anti‐tumour
responses.1 Anti‐CTLA4 therapy was the first FDA approved
immunotherapy and has achieved significant therapeutic effects in
metastatic melanoma.2 In non‐small cell lung cancer (NSCLC), anti‐
CTLA4 therapy only showed moderate therapeutic effects when
combined with chemotherapy.3 On the other hand, anti‐pro-
grammed cell death protein 1 (PD‐1) antibody has generated many
exciting data from recent clinical trials in several cancers including
NSCLC.4–6 Anti‐PD‐1 antibody blocks the interaction between PD‐1
and its ligand, programmed death‐ligand 1 (PD‐L1) and PD‐L2, leads
to the reversal of previously exhausted immune responses.7 Com-
bined anti‐CTLA4 and anti‐PD‐1 antibodies treatment was approved
in metastatic melanoma with better efficacy compare with single
agent.8,9 The rationale of the better efficacy is based on the obser-
vation that anti‐CTLA4 targets the circulating T cells and anti‐PD‐1
targets the tumour infiltrated T cells.10 Together, they function at
different steps to enhance T cell activation. Despite many pro-
gresses, only a fraction of patients with solid tumours benefits from
anti‐CTLA4 or anti‐PD‐1 treatment.5,7 Currently, PD‐L1 is the pre-
dictive biomarker for the responsiveness of anti‐PD‐1 treatment
with limited success.11
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It has been reported that CTLA4 and PD‐1 are expressed in
NSCLC tumour tissues and cell lines, but not in normal bronchial
epithelium.12–14 CTLA4 is expressed in many cell lines from variety
of solid tumours. Treatment with CTLA4 ligands CD80/CD86
induces apoptosis with activation of caspase‐8 and caspase‐3.13
CTLA4 expression levels in NSCLC cancer tissues have been studied
for its relevance in prognosis.12 These data indicate that tumour cell‐
intrinsic CTLA4 may play a role in tumorigenesis. Recently, mela-
noma cells were found to have tumour cell‐intrinsic expression of
PD‐1. The cell‐intrinsic PD‐1 engages with its ligand, PD‐L1, to pro-
mote tumorigenesis and modulate downstream mTOR signalling, in
the absence of adaptive immunity.15
The interactions among CTLA4, PD‐1/PD‐L1 and oncogenic
mutations are under investigation. In melanoma cells resistant to
combined anti‐CTLA4 and radiation treatment, they have elevated
PD‐L1 expression.16 CD4+ T cells from bladder cancer patients
receiving anti‐CTLA4 treatment had markedly increased production
of IFN‐γ.17 IFN‐γ is known to induce PD‐L1 expression.18 Oncogenic
EGFR activation has been found to up‐regulate PD‐1 and PD‐L1.19,20
PD‐L1 expression was associated with adenocarcinoma and EGFR
mutations.14
In order to understand whether CTLA4 is expressed in NSCLC,
whether tumour cell‐intrinsic CTLA4 plays a role in tumorigenesis,
we examined the CTLA4, PD‐1, PD‐L1 expression levels in multiple
NSCLC cell lines with different oncogenic mutations and in the tis-
sue samples from NSCLC patients. We found that CTLA4 was
expressed in a subset of NSCLC cell lines and in a subgroup of can-
cer cells within the lung cancer tissues. We further found that
tumour cell‐intrinsic CTLA4 regulates PD‐L1 expression and cell pro-
liferation via the EGFR pathway.
2 | MATERIALS AND METHODS
2.1 | Cell culture and reagents
Human NSCLC cell lines A549, H460, HCC827, H1975, H1650,
H661 cells were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). A549 CTLA4 knockout or EGFR
knockout cells were generated by CRISPR/Cas9 method. Stable
A549 CTLA4 overexpression cells were generated by Fugene
reagent (Promega, Madison, WI, USA). Anti‐CTLA4 and anti‐PD‐1
antibodies for Western blot and Immunohistochemistry (IHC) were
obtained from Abcam (Cambridge, MA, USA). Anti‐CTLA4 and anti‐
PD‐1 antibodies for in vivo treatment were obtained from Bio X
Cell (West Lebanon, NH, USA). Anti‐PD‐L1, EGFR, pEGFR, MEK,
pMEK, pERK, pS6 antibodies were obtained from Cell Signaling
(Danvers, MA, USA). IFN‐γ was obtained from Sigma‐Aldrich (St.
Louis, MO, USA). This study has collected FFPE cancer tissue from
NSCLC in patients who underwent surgical procedures at Zhong-
shan Hospital. The study protocol was approved by the internal
review board of Zhongshan Hospital. All patients gave signed, writ-
ten, informed consent on the use of clinical specimens for medical
research.
2.2 | Western blot
Cells were allowed to proliferate to 60%‐70% of maximum occu-
pancy on tissue culture plastic, and treated as indicated. For the
excised tumour, the tissues were homogenized on ice in cell lysis
buffer. The lysates containing equal amounts of protein were loaded
on a 10% SDS/PAGE gel. Antibodies for Western blot are as indi-
cated.
2.3 | Immunohistochemistry and
immunofluorescence staining
Formalin‐fixed paraffin embedded specimens were serially sectioned
at 5 um intervals and mounted on glass slides. IHC for CTLA4, PD‐1,
PD‐L1 were performed using the antibodies as indicated. NSCLC
cells were grown on chamber slides and were fixed with 4%
formaldehyde, followed by primary and secondary antibody. Cells
were counterstained with DAPI to show the nuclei.
2.4 | Generate CRISPR/Cas9 knockout NSCLC cells
We obtained the pSpCas9‐2A‐Puro (PX459) v2.0 Plasmid from
Addgene (Cambridge, MA, USA). DNA Oligos were synthesized and
ligated into PX459 according to the protocol.21 Plasmids were trans-
fected into A549 cells and stable cell lines were selected using puro-
mycin to generate A549 EGFR KO cells and A549 CTLA4 KO cells.
The effectiveness of knockout was determined by Western blot. Oligo
sequences for sgRNA are as the following: EGFR_sg_F1: 5‐CA
CCgTGAGCTTGTTACTCGTGCCT‐3; EGFR_sg_R1: 5‐AAACAG
GCACGAGTAACAAGCTCAc‐3; EGFR_sg_F2: 5‐CACCgGAGTAACAA
GCTCACGCAGT‐3; EGFR_sg_R2: 5‐AAACACTGCGTGAGCTTGTTA
CTCc‐3; CTLA4_sg_F1: 5‐CACCgGTACCCACCGCCATACTACC‐3;
CTLA4_sg_R1: 5‐AAACGGTAGTATGGCGGTGGGTACc‐3; CTLA4_sg_
F2: 5‐CACCgTTGCCTATGCCCAGGTAGTA‐3; CTLA4_sg_R2: 5‐AAA
CTACTACCTGGGCATAGGCAAc‐3.
2.5 | Cell proliferation MTT assay
Cell proliferation was determined by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐
diphenyltetrazolium bromide (MTT) assay. Cells (15 × 103) were
incubated in 96‐well plates for 24 hours in complete medium before
the addition of treatment as indicated. MTT solution (1 mg/mL;
Sigma‐Aldrich) was added to a final concentration of 0.4 mg/mL, and
plates were incubated at 37°C for 3 hours. The absorbance was
recorded at 540 nm. Statistical analyses were performed using Graph
Pad Prism software (GraphPad Software, La Jolla, CA, USA).
2.6 | Xenograft experiments
All studies were conducted in accordance with the University of
California San Diego Institutional Animal Care and Used Committee
(IACUC) and the National Institutes of Health guideline for the care
and use of laboratory animals. Nude mice (nu/nu) were obtained
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from Charles River Laboratories (Wilmington, MA, USA). At day 0, a
total of 5.0 × 106 cells (A549) were implanted subcutaneously into
the right flank of 6‐week‐old nude mice. At day 7, the average
tumour size reached 50‐100 mm3, mice were randomized and
divided into different treatment groups (n = 8 for each group).
Anti‐CTLA4 (clone BNI3), anti–PD‐1 (clone J116) or control IgG1
antibodies were administered at 200 μg in 100 μL of PBS by
intraperitoneal injection. The injections were done twice weekly.
The tumour sizes were measured twice weekly. At day 42, after
tumour diameters are measured, animals were sacrificed and
tumours were excised. Statistical analyses were performed using
Graph Pad Prism software.
3 | RESULTS
3.1 | CTLA4 and PD‐L1 are expressed in NSCLC
cell lines and tissue samples
We first examined the protein expression of CTLA4, PD‐1 and PD‐
L1 in a few NSCLC cell lines. By Western blotting, we found that
F IGURE 1 CTLA4 and PD‐L1
expression in NSCLC cells. A, CTLA4 is
expressed at various levels in NSCLC cell
lines. PD‐L1 is expressed in all NSCLC cell
lines. Individual cell line is as marked. B,
CTLA4 and PD‐L1 are localized in the
cytoplasm of NSCLC cells, with high
concentration of the protein is found to
surround the nuclear membrane. A549
cells are shown. C, NSCLC patient tissue
samples with mutations in K‐Ras (n = 3), in
EGFR (n = 3), without mutations in these
two genes (n = 3) were stained for CTLA4,
PD‐1 and PD‐L1, respectively. All samples
regardless of K‐Ras and EGFR mutation
status showed similar expression: CTLA4 is
expressed not only in tumour‐infiltrated
lymphocytes, but also lung cancer cells
(left). PD‐1 expression is undetectable in
the tissue samples we tested (middle). PD‐
L1 is expressed in a subgroup of cancer
cells within the lung cancer tissues from
NSCLC patients (right). Representative
images are shown. D, Higher
magnifications of regions boxed with
dashed lines in C. Scale bars are 50 μm
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CTLA4 and PD‐L1 are expressed at various levels in NSCLC cell
lines. Both CTLA4 and PD‐L1 are expressed in A549, H460,
HCC827, H1975 cells at relatively high levels. They are expressed in
H661 cells at very low levels, and are not expressed at H1650 cells
(Figure 1A). PD‐1 is expressed at low levels in all these cells (data
not shown). In normal bronchial epithelial cells, BEAS‐2B, there is no
detectable expression of CTLA4 or PD‐1 (data not shown). By
immunostaining, we again found that CTLA4 and PD‐L1 are
expressed in NSCLC cells (Figure 1B). In the lung cancer tissue sam-
ples from NSCLC patients, CTLA4 and PD‐L1, are expressed not only
in tumour‐infiltrated lymphocytes, but also lung cancer cells (Fig-
ure 1C,D). On the other hand, PD‐1 is barely detectable in the tissue
samples from NSCLC patients (Figure 1C and D).
3.2 | Anti‐CTLA4 increases PD‐L1 expression in
NSCLC cell lines
The similar expression pattern of CTLA4 and PD‐L1 in lung cancer
cells prompted us to investigate whether one protein affect the
expression of the other. In melanoma, it has been shown that anti‐
CTLA4 antibody treatment initially reduces tumour burden, but the
resistant cancer cells have increased PD‐L1 expression.16 We found
that anti‐CTLA4 antibody, when present in the culture media,
increased PD‐L1 expression in NSCLC cell lines (Figure 2A). IFN‐γ,
which is known to stimulate PD‐L1 expression,18 was used as a posi-
tive control. The anti‐CTLA4 antibody induced up‐regulation of PD‐
L1 is observed in the cell lines with higher CTLA4 expression, such
as in A549, H460, HCC827 and H1975, but not in those with low
or no CTLA4 expression, such as H661 and H1650 (Figure 2A).
These cells are EGFR wild‐type or EGFR activating mutations NSCLC
cells. Using fluorescent immune staining of A549 cells, we observed
that, while IFN‐γ induced PD‐L1 expression in all cells, anti‐CTLA4
did so in a subset of cells (Figure 2B).
To understand if the regulation is at transcriptional level, we
measured PD‐L1 mRNA levels in cells after treatment with IFN‐γ or
anti‐CTLA4. We found that A549 cells, but not H661 cells,
responded to the treatment by increasing PD‐L1 mRNA (Figure S1),
consistent with changes in protein levels measured by Western
F IGURE 2 Effects of IFN‐γ and anti‐
CTLA4 antibody treatment on PD‐L1
expression in NSCLC cells. A, The
indicated cells were treated with IFN‐γ
(100 ng/mL) or anti‐CTLA4 antibody
(10 μg/mL) for 24 h. The anti‐CTLA4
antibody induced up‐regulation of PD‐L1
was observed in A549, H460, HCC827
and H1975, but not in H661 and H1650
cells. B, IFN‐γ or Anti‐CTLA4 antibody
treatment increases cellular PD‐L1 (red) in
A549 cells. Scale bars are 50 μm
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blots. Thus, anti‐CTLA4 seems to increase PD‐L1 transcription in a
subset of NSCLC cells.
3.3 | Anti‐CTLA4 induced up‐regulation of PD‐L1 is
mediated by EGFR pathway
We then investigated the mechanisms that mediated the anti‐
CTLA4 induced PD‐L1 expression. Based on our findings that both
CTLA4 and PD‐L1 are expressed at higher levels in EGFR wild‐
type or EGFR activating mutations NSCLC cells (Figure 2A), we
focused on determining the EGFR activation status. We found
that the level of phosphorylated EGFR (pEGFR) was indeed
increased after anti‐CTLA4 antibody treatment in a dose‐depen-
dent manner, whereas the total EGFR levels were not changed
(Figure 3A). IFN‐γ treatment, on the other hand, did not alter
pEGFR levels (Figure 3A).
To further substantiate this finding, we examined the levels of
EGFR downstream components, phosphorylated MEK (pMEK) and
phosphorylated ERK (pERK). We found that anti‐CTLA4 also
increased pMEK, pERK levels in a dose‐dependent manner
F IGURE 3 Anti‐CTLA4 induced PD‐L1
expression is EGFR pathway dependent in
NSCLC cells. A, The A549 cells or H460
cells were treated with IFN‐γ (100 ng/mL)
or anti‐CTLA4 antibody (10, 50 μg/mL) for
24 h. Anti‐CTLA4 antibody increases
pEGFR, but not total EGFR, in a dose‐
dependent manner. The increase of pEGFR
is in parallel with the increase of PD‐L1. B,
Anti‐CTLA4 antibody increases pMEK,
pERK levels, not the total MEK or pS6.
IFN‐γ increases the pS6 levels, but not the
pMEK or pERK levels. C, EGFR inhibitor,
Canertinib, inhibits pEGFR and anti‐CTLA4
induced up‐regulation of PD‐L1. Canertinib
has no effect on IFN‐γ induced PD‐L1
expression. D, In A549 EGFR knockout
(KO) cells, anti‐CTLA4 is unable to induce
PD‐L1 expression (lane 6). In A549 CTLA4
KO cells, anti‐CTLA4 induced up‐regulation
of PD‐L1 is diminished (lane 9). IFN‐γ
induced PD‐L1 expression is not affected
by EGFR KO (lane 5) or CTLA4 KO (lane 8)
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(Figure 3B). In contrast, IFN‐γ increases phosphorylated S6 Riboso-
mal Protein (pS6) levels without altering pMEK and pERK levels
(Figure 3B). Next, we examined the effects of EGFR inhibition or
EGFR knockout on anti‐CTLA4 induced PD‐L1 expression. We
found that the EFGR inhibitor Canertinib suppressed pEGFR levels
and also suppressed anti‐CTLA4 induced PD‐L1 expression levels
(Figure 3C, lane 4). Of note, Canertinib has no effect on IFN‐γ
induced PD‐L1 expression (Figure 3C, lane 3). We then generated
A549 EGFR knockout (KO) cells and A549 CTLA4 KO cells by
CRISPR/Cas9. In EGFR KO cells, anti‐CTLA4 is unable to induce
PD‐L1 expression (Figure 3D, lane 6), while IFN‐γ induced PD‐L1
expression is intact (Figure 3D, lane 5). In CTLA4 KO cells, the
anti‐CTLA4 induced up‐regulation of PD‐L1 is diminished too
(Figure 3D, lane 9). Again, IFN‐γ induced PD‐L1 expression is
intact (Figure 3D, lane 8).
3.4 | Effects of anti‐CTLA4 antibody on cancer cell
proliferation in vitro and tumour growth in vivo
Based on our finding that anti‐CTLA4 antibody activates the EGFR
pathway in NSCLC cells, we investigated its effects on cell prolif-
eration. We used MTT assay in A549 cells, A549 CTLA4 KO cells
and A549 CTLA4 overexpression (OE) cells. We found that anti‐
CTLA4 antibody treatment promoted cell proliferation in A549
cells (Figure 4A), more so in A549 CTLA4 OE cells, but not in
A549 CTLA4 KO cells (Figure 4A). We next examined the effects
of anti‐CTLA4 and anti‐PD‐1 treatment on xenograft tumour
growth in nude mice. Nude mice do not have T cells, allowing for
evaluating the function of tumour cell‐intrinsic CTLA4 in the
absence of adaptive immunity. We found that anti‐CTLA4 anti-
body increased the xenograft tumour growth compared with con-
trol IgG treatment (Figure 4B). Anti‐PD‐1 antibody decreases the
xenograft tumour growth. Combination of anti‐CTLA4 and anti‐PD‐
L1 antibodies further decreases the tumour growth (Figure 4B). In
the excised tumour tissue, anti‐CTLA4 antibody increases the PD‐
L1 expression, whereas anti‐PD‐1 antibody does not have signifi-
cant effects on PD‐L1 expression. Combination of anti‐CTLA4 and
anti‐PD‐1 antibodies increases PD‐L1 expression in the tumour
tissue (Figure 4C).
4 | DISCUSSION
Our current knowledge about CTLA4 and PD‐1 are mostly based on
their functions in T cells.22 Although CTLA4 expression levels have
been studied for the relevance of prognosis in NSCLC,12 and CTLA4
was found to be expressed in multiple tumours including
NSCLC,12,13,23,24 no further studies were done to reveal its function
in tumour cells. We demonstrated that CTLA4 was expressed in a
subset of NSCLC cell lines and in a subgroup of cancer cells within
the lung cancer tissues. The expression levels of CTLA4 and PD‐L1
correlate with each other and they are both higher in EGFR wild‐
type or EGFR activating mutations NSCLC cells.
It has been reported that the EGFR and Hippo/YAP pathways
are involved in regulation of PD‐L1 expression.14,19,25–27 We pro-
vided the evidence that anti‐CTLA4 antibody could induce PD‐L1
expression in NSCLC cells. However, anti‐CTLA4 was unable to
induce PD‐L1 expression in CTLA4 KO or EGFR KO cells, or in the
presence of an EGFR‐specific tyrosine kinase inhibitor. CTLA4 and
EGFR are both required for anti‐CTLA4 induced PD‐L1 up‐regulation
in NSCLC cells. These results indicate that anti‐CTLA4 antibody
binds to the tumour cell‐intrinsic CTLA4 on the cell surface, resulting
in activation of the EGFR pathway, which induces PD‐L1 expression.
Anti‐CTLA4 and IFN‐γ use different pathways to regulate PD‐L1
expression, with anti‐CTLA4 activating the EGFR pathway and IFN‐γ
functioning through the mTOR/S6 pathway.28
F IGURE 4 Effects of anti‐CTLA4 antibody on cell proliferation
and tumour growth in the absence of adaptive immunity. A, In
A549, A549 CTLA4 KO and A549 CTLA4 overexpression (OE) cells,
anti‐CTLA4 antibody treatment promoted cell proliferation in A549
cells, more so in A549 CTLA4 OE cells, but not in A549 CTLA4 KO
cells. Data are shown as means ± SEM (n = 10), compared with
A549 control group, P < 0.05, P < 0.01 as marked. B, In nude mice
xenograft experiments, anti‐CTLA4 antibody increases the xenograft
tumour growth compared with control IgG treatment. Data are
shown as means ± SEM (n = 8), compared with control IgG group,
*a, P < 0.05. Anti‐PD‐1 antibody has negative effects on tumour
growth but not significant. The combination of anti‐CTLA4 and anti‐
PD‐L1 antibodies significantly decreased the tumour growth. Data
are shown as means ± SEM (n = 8), compared with control IgG
group, *b, P < 0.05. C. In the excised xenograft tumour, anti‐CTLA4
antibody increases the PD‐L1 expression. The combination of anti‐
CTLA4 and anti‐PD‐1 antibodies further increases PD‐L1 expression
in the tumour tissue
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We found that anti‐CTLA4 antibody could promote NSCLC cell
proliferation in vitro. The cell proliferation was further increased in
A549 CTLA4 OE cells, but was diminished in A549 CTLA4 KO cells.
The xenograft tumour growth in vivo studies were done in the
absence of adaptive immunity. Anti‐CTLA4 antibody again promoted
NSCLC tumour growth. These data suggest that tumour cell‐intrinsic
CTLA4 plays a role in tumorigenesis. This may explain the lack of
efficacy of anti‐CTLA4 treatment in NSCLC. NSCLC patients
received anti‐CTLA4 antibody may have beneficial effects from the
circulating T cells activation, but anti‐CTLA4 antibody also promotes
NSCLC cell proliferation via the tumour cell‐intrinsic CTLA4. Combi-
nation of anti‐CTLA4 and anti‐PD‐1 antibodies have better efficacy
than anti‐PD‐1 antibody alone. These results were not explained by
the previous rationale that better efficacy was due to anti‐CTLA4
and anti‐PD‐1 acting at different steps to enhance T cell activation,10
because the nude mice are lacking of immune cells. In the excised
tumour tissue, PD‐L1 expression was increased in anti‐CTLA treat-
ment group. The combination of anti‐CTLA4 and anti‐PD‐1 antibod-
ies further increased PD‐L1 expression. These data suggest that the
increased PD‐L1 expression in the tumour cells may provide the tar-
get for anti‐PD‐1 antibody for potentiating the tumour suppression.
Our results advanced our current understanding of the function
of CTLA4 in NSCLC. The tumour cell‐intrinsic expression of CTLA4
has a different function than that of the checkpoint protein in T
cells. Anti‐CTLA4 antibody binds with the tumour cell‐intrinsic
CTLA4 and activates the EGFR pathway to induce PD‐L1 expression.
A panel of CTLA4, PD‐1, PD‐L1, EGFR expression levels may better
predict the responsiveness of anti‐PD‐1 treatment compared with
the PD‐L1 as a single predictive biomarker. Tumour cell‐intrinsic
CTLA4 expression provides us new therapeutic target for NSCLC
treatment. In NSCLC with wild‐type EGFR and high expression levels
of CTLA4, anti‐CTLA4 antibody may induce PD‐L1 expression to
potentiate the efficacy of anti‐PD‐1 treatment. Other molecules or
peptides that can activate the tumour cell‐intrinsic CTLA4 will be
worthwhile to investigate.
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